SINCE 2005

• Menactra was first licensed in 2005 and received FDA approval to be administered as a 2nd dose to adolescents and adults in 2014^5,6

PRIMARY VACCINATION:

• In children 9 through 23 months of age, Menactra is given as a 2-dose series,
  3 months apart⁵
• In individuals 2 through 55 years of age, Menactra is given as a single dose⁵

BOOSTER VACCINATION:

• A single booster dose of Menactra may be given to individuals 15 through
  55 years of age at continued risk for meningococcal disease if at least
  4 years have elapsed since the prior dose⁵

IMMUNOGENICITY

• A 2nd dose of Menactra induced
  protective titer levels in more
  than
  99% of trial participants^5,7

2nd Dose Immunogenicity in Adolescents
and Adults

Study Design: A phase 2, open-label study was conducted between September 2011 and July 2012 at 15 centers
in the US that evaluated the safety and immunogenicity of a single booster dose of Menactra at 4 to 6 years after
prior vaccination in persons first vaccinated at 11 through 55 years of age. A total of 834 participants were enrolled;
of these, 781 met criteria for inclusion in the per-protocol population for the immunogenicity analysis.⁵

SAFETY

FIRST DOSE:

• The most common solicited injection site and systemic adverse reactions within 7 days after a single dose of Menactra in adolescents aged 11 to 18 years were injection site pain (59.2%), headache (35.6%), and fatigue (30%)⁵

SECOND DOSE:

• The most common solicited injection site and systemic adverse reactions within 7 days after a second dose of Menactra in adolescents and adults were pain (60.2%) and myalgia (42.8%)⁵

NO RECONSTITUTION REQUIRED